Nonalcoholic steatohepatitis: A twenty-first century epidemic?

Journal of Clinical Gastroenterology

Volumn 40, Issue SUPPL. 1, 2006, Pages

  Kowdley, Kris V ^a,c   Caldwell, Stephen ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Box 356174 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALPHA TOCOPHEROL; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; BETAINE; CLOFIBRATE; FATTY ACID; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

APOPTOSIS; ASIAN AMERICAN; BARIATRIC SURGERY; BEHAVIOR MODIFICATION; BIOACCUMULATION; BODY FAT DISTRIBUTION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG POTENCY; EPIDEMIC; EPIDEMIOLOGICAL DATA; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FIBROGENESIS; GLUCONEOGENESIS; GLUCOSE TOLERANCE; HIGH RISK POPULATION; HISPANIC; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INCIDENCE; INSULIN RESISTANCE; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER METABOLISM; LIVER NECROSIS; METABOLIC DISORDER; METABOLIC SYNDROME X; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POPULATION RISK; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STOMACH BYPASS; TREATMENT INDICATION; WEIGHT REDUCTION;

DISEASE PROGRESSION; ETHNIC GROUPS; FATTY LIVER; FEMALE; HUMANS; INCIDENCE; MALE; PREVALENCE; UNITED STATES;

EID: 33748153616     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000168639.61970.3     Document Type: Conference Paper

References (35)

1. Division of Adult and Community Health: National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Online Prevalence Data. Centers for Disease Control and Prevention, 1995-2003.
2. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89:2583-2589.
3. Collantes R, Ong JP, Younossi ZM. Nonalcoholic fatty liver disease and the epidemic of obesity. Cleve Clin J Med. 2004;71:657-664.
4. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395.
5. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438.
6. Caldwell SH, Crespo DM, Kang HS, et al. Obesity and hepatocellular carcinoma. Gastroenterology. 2004;127(suppl 1):97-103.
7. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:521-533.
8. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37: 1202-1219. Erratum in: Hepatology. 2003;38:536.
9. Contos MJ, Choudhury J, Mills AS, et al. The histologic spectrum of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:481-500.
10. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127(suppl 1):27-34.
11. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638.
12. Day CP, James OF. Steatohepatitis: a tale of two 'hits?' Gastroenterology. 1998;11:842-845.
13. Roden M, Stingl H, Chandramouli V, et al. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeo genesis in humans. Diabetes. 2000;49:701-707.
14. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:575-594.
15. Hayashi T, Boyko EJ, Leonetti DL, et al. Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans. Diabetes Care. 2003;26:650-655.
16. Purnell JQ, Kahn SE, Schwartz RS, et al. Relationship of insulin sensitivity and ApoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2001;21:567-572.
17. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147-152.
18. Cortez-Pinto H, Zhi Lin H, Qi Yang S, et al. Lipids up-regulate uncoupling protein 2 expression in rat hepatocytes. Gastroenterology. 1999;116:1184-1193.
19. Emery MG, Fisher JM, Chien JY, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology. 2003;38:428-435.
20. Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis. 2004;14:228-232.
21. Chalasani N, Crabb DW, Cummings OW, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol. 2003;98:2771-2776.
22. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology. 2002;36:403-409.
23. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 20041;40:46-54.
24. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004;53:413-419.
25. Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647-1654.
26. Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004;1:23-28.
27. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893-894.
28. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003;38:1008-1017.
29. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004;2:1107-1115.
30. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39:188-196.
31. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485-2490.
32. Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38:413-419.
33. Harrison SA, Fincke C, Helinski D, et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther. 2004;20:623-628.
34. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996;23:1464-1467.
35. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770-778.